Table 1 Demographics of the study population.

From: Potential of biomarker-based enrichment strategies to identify critically ill patients for emerging cell death interventions

Characteristics

Total cohort (n = 176)

Age, years

 Median (IQR)

61 (19)

 Min-max range

18-86

Gender, n (%)

 Male

107 (61)

 Female

69 (39)

Body mass index (BMI), kg/m2

 Median (IQR)

24.22 (5.38)

 Min-max range

15.62–42.45

Highest SOFA during ICU

 Median (IQR)

9 (4)

 Min-max range

2–19

Highest APACHE II during ICU

 Median (IQR)

27 (7)

 Min-max range

6–43

Sepsis stage on day 1, n (%)

 No sepsis

58 (33)

 Sepsis

61 (35)

 Septic shock

31 (18)

 No data

26 (15)

AKI stage on day 1, n (%)

 No AKI

138 (78)

 Stage 1

35 (20)

 Stage 2

3 (2)

 Stage 3

0 (0)

Survival at day 30, n (%)

 Survived

135 (77)

 Deceased

41 (23)

Diabetes, n (%)

 Yes

12 (7)

 No

164 (93)

Corticosteroids (chronic), n (%)

 Yes

22 (12)

 No

154 (88)

NSAID (chronic), n (%)

 Yes

10 (6)

 No

166 (94)

Mechanical ventilation on day 1, n (%)

 Yes

117 (66)

 No

59 (34)

Time in the hospital, days

 Median (IQR)

21 (30)

 Min-max range

1–492

Reason for hospital admission

 Elective surgery

21 (12)

 Medical

107 (61)

 Urgent surgery

48 (28)

Referred from

 Other hospital

37 (21)

 Emergency room

74 (42)

 Operating room

18 (10)

 Floor

47 (27)

  1. IQR interquartile range, AKI acute kidney injury, SOFA sequential organ failure assessment, NSAID non-steroidal anti-inflammatory drug, APACHE II Acute Physiology and Chronic Health Evaluation II.